Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1233069.RAZU-w-Sa040ULAzEdftQQwqkkkomR1LcaHIXK2V5dHd4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1233069.RAZU-w-Sa040ULAzEdftQQwqkkkomR1LcaHIXK2V5dHd4130_assertion type Assertion NP1233069.RAZU-w-Sa040ULAzEdftQQwqkkkomR1LcaHIXK2V5dHd4130_head.
- NP1233069.RAZU-w-Sa040ULAzEdftQQwqkkkomR1LcaHIXK2V5dHd4130_assertion description "[Alectinib/CH5424802 is a known inhibitor of anaplastic lymphoma kinase (ALK) and is being evaluated in clinical trials for the treatment of ALK fusion-positive non-small cell lung cancer (NSCLC).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1233069.RAZU-w-Sa040ULAzEdftQQwqkkkomR1LcaHIXK2V5dHd4130_provenance.
- NP1233069.RAZU-w-Sa040ULAzEdftQQwqkkkomR1LcaHIXK2V5dHd4130_assertion evidence source_evidence_literature NP1233069.RAZU-w-Sa040ULAzEdftQQwqkkkomR1LcaHIXK2V5dHd4130_provenance.
- NP1233069.RAZU-w-Sa040ULAzEdftQQwqkkkomR1LcaHIXK2V5dHd4130_assertion SIO_000772 25349307 NP1233069.RAZU-w-Sa040ULAzEdftQQwqkkkomR1LcaHIXK2V5dHd4130_provenance.
- NP1233069.RAZU-w-Sa040ULAzEdftQQwqkkkomR1LcaHIXK2V5dHd4130_assertion wasDerivedFrom befree-2016 NP1233069.RAZU-w-Sa040ULAzEdftQQwqkkkomR1LcaHIXK2V5dHd4130_provenance.
- NP1233069.RAZU-w-Sa040ULAzEdftQQwqkkkomR1LcaHIXK2V5dHd4130_assertion wasGeneratedBy ECO_0000203 NP1233069.RAZU-w-Sa040ULAzEdftQQwqkkkomR1LcaHIXK2V5dHd4130_provenance.